Literature DB >> 15959528

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.

M Yanada1, K Matsuo, T Suzuki, H Kiyoi, T Naoe.   

Abstract

Two distinct forms of fms-like tyrosine kinase (FLT3) gene aberrations, internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, have been recognized in a substantial proportion of patients with acute myeloid leukemia (AML). To investigate their prognostic significance, we performed a meta-analysis of the four published studies that provided survival information according to the FLT3 status: ITD, TKD mutation, and wild type. The summary hazard ratios for disease-free survival (DFS) were 1.88 (95% confidence interval (CI) 1.58-2.23; P<0.001) for FLT3 mutations, 1.86 (95% CI: 1.52-2.29; P<0.001) for ITD, and 1.90 (95% CI: 1.40-2.60; P<0.001) for TKD mutation. The corresponding ratios for overall survival were 1.61 (95% CI: 1.37-1.89; P<0.001), 1.68 (95% CI: 1.39-2.03; P<0.001), and 1.37 (95% CI: 0.94-2.01; P=0.104). Neither white blood cell count at diagnosis nor cytogenetic risk category was a significant source of heterogeneity. These findings indicate that FLT3 mutations have an adverse effect on the outcome for AML, and that the negative impact of TKD mutation seems comparable to that of ITD with regard to DFS. Although it should be borne in mind that this meta-analysis was based on data abstracted from observational studies, these results may justify the risk-adapted therapeutic strategies for AML according to the FLT3 status. Leukemia (2005) 19, 1345-1349.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959528     DOI: 10.1038/sj.leu.2403838

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  72 in total

1.  Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.

Authors:  Edward Agura; Barry Cooper; Houston Holmes; Estil Vance; Robert Brian Berryman; Christopher Maisel; Sandy Li; Giovanna Saracino; Mirjana Tadic-Ovcina; Joseph Fay
Journal:  Oncologist       Date:  2011-01-27

Review 2.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 3.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

4.  FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.

Authors:  Lei Wang; Wei-lai Xu; Hai-tao Meng; Wen-bin Qian; Wen-yuan Mai; Hong-yan Tong; Li-ping Mao; Yin Tong; Jie-jing Qian; Yin-jun Lou; Zhi-mei Chen; Yun-gui Wang; Jie Jin
Journal:  J Zhejiang Univ Sci B       Date:  2010-10       Impact factor: 3.066

Review 5.  Progress in acute myeloid leukemia.

Authors:  Tapan M Kadia; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09-19

Review 6.  Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.

Authors:  Jo Ishizawa; Kensuke Kojima; Numsen Hail; Yoko Tabe; Michael Andreeff
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

7.  MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Authors:  Suiyang Liu; Li Yin; Dina Stroopinsky; Hasan Rajabi; Alexandre Puissant; Kimberly Stegmaier; David Avigan; Surender Kharbanda; Donald Kufe; Richard Stone
Journal:  Blood       Date:  2013-11-26       Impact factor: 22.113

8.  Prognostic significance of B-cell lymphoma 2 expression in acute leukemia: A systematic review and meta-analysis.

Authors:  Yanfeng Liu; Pengcheng He; Feng Liu; Lili Shi; Huachao Zhu; Xiaoyan Cheng; Jing Zhao; Yuan Wang; Mei Zhang
Journal:  Mol Clin Oncol       Date:  2014-01-24

9.  Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.

Authors:  Nada Assaf; Jean El-Cheikh; Ali Bazarbachi; Ziad Salem; Chantal Farra; Zaher Chakhachiro; Samer Nassif; Ghazi Zaatari; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2019-01-30       Impact factor: 2.316

10.  Backseat drivers take the wheel.

Authors:  P Andrew Futreal
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.